Tezspire 210 mg solution for injection in pre-filled syringe, Tezepelumab-placebo
CROSSING
Phase 3 small_molecule active
Quick answer
Tezspire 210 mg solution for injection in pre-filled syringe, Tezepelumab-placebo for Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active